Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
PaperCitations, authors & open-access status
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 401 citations, 2021 year and closed oa status.
401
Citations
2021
Year
closed
OA Status